Barrons.com
Netflix Is Casting a Light on a Rare Disease. Pearl Jam’s Frontman Is Raising Cash to Cure It.
➖
AI Sentiment
Neutral
5/10
- Home
- ABEO
as of 02-13-2026 3:46pm EST
$5.01
+$0.01
+0.30%
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
| Founded: | 1974 | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 280.2M | IPO Year: | 1980 |
| Target Price: | $18.20 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.93 - $7.54 | Next Earning Date: | 03-19-2026 |
| Revenue: | $400,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1589.77% |
| P/E Ratio: | 3.89 | Index: | N/A |
| Free Cash Flow: | -82360000.0 | FCF Growth: | N/A |
AI-Powered ABEO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 70.13%
70.13%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)
Alvino Mark
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
2,000
Total Value
$10,181.20
Owned After
84,065
SEC Form 4
Crombez Eric
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
16,284
Total Value
$82,895.33
Owned After
63,456
SEC Form 4
Alland Leila
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
18,065
Total Value
$91,961.69
Owned After
173,614
SEC Form 4
Silverstein Christine Berni
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
20,070
Total Value
$102,168.34
Owned After
137,722
SEC Form 4
Wuchterl Donald A.
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
14,814
Total Value
$75,412.15
Owned After
167,935
SEC Form 4
O'Malley Brendan M.
Sell
SVP, Chief Legal Officer
ABEO Jan 22, 2026
Avg Cost/Share
$5.33
Shares
13,578
Total Value
$72,382.96
Owned After
451,134
SEC Form 4
Vazzano Joseph Walter
Sell
Chief Financial Officer
ABEO Jan 22, 2026
Avg Cost/Share
$5.33
Shares
18,666
Total Value
$99,506.58
Owned After
568,560
SEC Form 4
Seshadri Vishwas
Sell
Chief Executive Officer
ABEO Jan 22, 2026
Avg Cost/Share
$5.33
Shares
69,832
Total Value
$372,267.41
Owned After
1,460,408
SEC Form 4
Vasanthavada Madhav
Sell
Chief Commercial Officer
ABEO Jan 22, 2026
Avg Cost/Share
$5.29
Shares
12,610
Total Value
$66,657.72
Owned After
318,619
SEC Form 4
Alvino Mark
Sell
Director
ABEO Jan 21, 2026
Avg Cost/Share
$5.23
Shares
13,500
Total Value
$70,573.95
Owned After
84,065
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Alvino Mark | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 2,000 | $10,181.20 | 84,065 | |
| Crombez Eric | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 16,284 | $82,895.33 | 63,456 | |
| Alland Leila | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 18,065 | $91,961.69 | 173,614 | |
| Silverstein Christine Berni | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 20,070 | $102,168.34 | 137,722 | |
| Wuchterl Donald A. | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 14,814 | $75,412.15 | 167,935 | |
| O'Malley Brendan M. | ABEO | SVP, Chief Legal Officer | Jan 22, 2026 | Sell | $5.33 | 13,578 | $72,382.96 | 451,134 | |
| Vazzano Joseph Walter | ABEO | Chief Financial Officer | Jan 22, 2026 | Sell | $5.33 | 18,666 | $99,506.58 | 568,560 | |
| Seshadri Vishwas | ABEO | Chief Executive Officer | Jan 22, 2026 | Sell | $5.33 | 69,832 | $372,267.41 | 1,460,408 | |
| Vasanthavada Madhav | ABEO | Chief Commercial Officer | Jan 22, 2026 | Sell | $5.29 | 12,610 | $66,657.72 | 318,619 | |
| Alvino Mark | ABEO | Director | Jan 21, 2026 | Sell | $5.23 | 13,500 | $70,573.95 | 84,065 |
Latest Abeona Therapeutics Inc. News
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
Compare ABEO vs Leading Stocks
See how ABEO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.